OpenLB
Open Library of Bioscience
Advanced Search
Current opinion in infectious diseases
Apr 01, 2025;38 (2): 122-127.

Omadacycline for the treatment of skin and soft tissue infections.

Antonio Vena, Nadia Castaldo, Daniele Roberto Giacobbe, Alberto Fantin, Matteo Bassetti
Author Information
  1. Antonio Vena: Department of Health Sciences (DISSAL), University of Genoa.
  2. Nadia Castaldo: Department of Pulmonology, University of Udine and Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy.
  3. Daniele Roberto Giacobbe: Department of Health Sciences (DISSAL), University of Genoa.
  4. Alberto Fantin: Department of Pulmonology, University of Udine and Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy.
  5. Matteo Bassetti: Department of Health Sciences (DISSAL), University of Genoa.
PMID: 39786987 DOI: 10.1097/QCO.0000000000001089

Abstract

PURPOSE OF REVIEW: To evaluate the current evidence on the use of Omadacycline for the treatment of skin and soft tissue infections (SSTIs).
RECENT FINDINGS: This narrative review examines the available data on the pharmacology, clinical efficacy, safety profile, and comparative effectiveness of Omadacycline in treating SSTIs, with a focus on its potential role in everyday clinical practice.
SUMMARY: Omadacycline is a viable option for outpatient therapy and early discharge in patients with SSTIs, particularly in frail populations and those undergoing chronic polypharmacotherapy. Emerging real-world evidence highlights its potential utility beyond approved indications, particularly for infections caused by multidrug-resistant microorganisms where treatment options are limited. However, further studies are needed to confirm its role in contexts beyond its current approvals.

References

  1. Vella V, Derreumaux D, Aris E, Pellegrini M, et al. The incidence of skin and soft tissue infections in the United States and associated healthcare utilization between 2010 and 2020. Open Forum Infect Dis 2024; 11:ofae267.
  2. Bassetti M, Nicco E, Mikulska M. Why is community-associated MRSA spreading across the world and how will it change clinical practice? Int J Antimicrob Agents 2009; 34: (Suppl 1): S15���S19.
  3. Bassetti M, Magnasco L, Del Puente F, Giacobbe DR. Role of new antibiotics in the treatment of acute bacterial skin and skin-structure infections. Curr Opin Infect Dis 2020; 33:110���120.
  4. Kaye KS, Petty LA, Shorr AF, et al. Current epidemiology, etiology, and burden of acute skin infections in the United States. Clin Infect Dis 2019; 68: (Suppl 3): S193���S199.
  5. Hersh AL, Chambers HF, Maselli JH, et al. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med 2008; 168:1585���1591.
  6. Edelsberg J, Taneja C, Zervos M, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis 2009; 15:1516���1518.
  7. Kaye KS, Patel DA, Stephens JM, et al. Rising United States hospital admissions for acute bacterial skin and skin structure infections: recent trends and economic impact. PLoS One 2015; 10:e0143276.
  8. Suaya JA, Mera RM, Cassidy A, et al. Incidence and cost of hospitalizations associated with Staphylococcus aureus skin and soft tissue infections in the United States from 2001 through 2009. BMC Infect Dis 2014; 14:296.
  9. Russo A, Concia E, Cristini F, et al. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections. Clin Microbiol Infect 2016; 22: (Suppl 2): S27���36.
  10. Moet GJ, Jones RN, Biedenbach DJ, et al. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2007; 57:7���13.
  11. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis 2006; 43:518���524.
  12. Overcash SJTE, Manley A, Sirbu A, et al. Omadacycline in female adults with cystitis: results from a randomized, double-blinded, adaptive phase 2 study. Open Forum Infect Dis 2020; 7: (Suppl 1): S827���S828.
  13. Zhanel GG, Esquivel J, Zelenitsky S, et al. Omadacycline: a novel oral and intravenous aminomethylcycline antibiotic agent. Drugs 2020; 80:285���313.
  14. Withdrawal of Marketing Authorisation Application for NUZYRA, omadacycline, 2019 EMA/556620/2019 EMEA/H/C/004715. Available at https://www.ema.europa.eu/en/documents/medicine-qa/questions-and-answers-withdrawal-application-marketing-authorisation-nuzyra-omadacycline_en.pdf . [Accessed 12 December 2024].
  15. Gallagher JC. Omadacycline: a modernized tetracycline. Clin Infect Dis 2019; 69: (Suppl 1): S1���S5.
  16. Draper MP, Weir S, Macone A, et al. Mechanism of action of the novel aminomethylcycline antibiotic omadacycline. Antimicrob Agents Chemother 2014; 58:1279���1283.
  17. Montravers P, Tran-Dinh A, Tanaka S. The role of omadacycline in skin and soft tissue infections. Curr Opin Infect Dis 2018; 31:148���154.
  18. Macone AB, Caruso BK, Leahy RG, et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother 2014; 58:1127���1135.
  19. Huband MD, Pfaller MA, Shortridge D, et al. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: results from the SENTRY Antimicrobial Surveillance Programme, 2017. J Glob Antimicrob Resist 2019; 19:56���63.
  20. Bassetti M, Giacobbe DR, Castaldo N, et al. Role of new antibiotics in extended-spectrum beta-lactamase-, AmpC- infections. Curr Opin Infect Dis 2021; 34:748���755.
  21. Flarakos J, Du Y, Gu H, et al. Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline. Xenobiotica 2017; 47:682���696.
  22. Paratek Pharmaceuticals I. NUZYRA [package insert]. Boston, MA: Paratek Pharmaceuticals I; 2018.
  23. Sun H, Ting L, Machineni S, et al. Randomized, open-label study of the pharmacokinetics and safety of oral and intravenous administration of omadacycline to healthy subjects. Antimicrob Agents Chemother 2016; 60:7431���7435.
  24. Tzanis E, Manley A, Villano S, et al. Effect of food on the bioavailability of omadacycline in healthy participants. J Clin Pharmacol 2017; 57:321���327.
  25. Gotfried MH, Horn K, Garrity-Ryan L, et al. Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects. Antimicrob Agents Chemother 2017; 61:e01135-17.
  26. Berg JK, Tzanis E, Garrity-Ryan L, et al. Pharmacokinetics and safety of omadacycline in subjects with impaired renal function. Antimicrob Agents Chemother 2018; 62:e02057-17.
  27. Cornely OA, File TM Jr, Garrity-Ryan L, et al. Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment. Int J Antimicrob Agents 2021; 57:106263.
  28. O���Riordan W, Green S, Overcash JS, et al. Omadacycline for acute bacterial skin and skin-structure infections. N Engl J Med 2019; 380:528���538.
  29. O���Riordan W, Cardenas C, Shin E, et al. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, noninferiority trial. Lancet Infect Dis 2019; 19:1080���1090.
  30. Sakoulas G, Eckburg PB, Amodio-Groton M, et al. Clinical efficacy of patients with secondary bacteremia treated with omadacycline: results from phase 3 acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia studies. Open Forum Infect Dis 2021; 8:ofab136.
  31. Villano S TS. Double-blind, randomized study of the effects of a supratherapeutic iv dose of omadacycline on QT/QTc intervals in healthy subjects 26th European Congress of Clinical Microbiology and Infectious Diseases; 9-12 April 2016; Amsterdam, The Netherlands.
  32. Opal S, File TM, van der Poll T, et al. An integrated safety summary of omadacycline, a novel aminomethylcycline antibiotic. Clin Infect Dis 2019; 69: (Suppl 1): S40���S47.
  33. Pai MP, Wilcox MH, Chitra S, et al. Safety and efficacy of omadacycline by BMI categories and diabetes history in two Phase III randomized studies of patients with acute bacterial skin and skin structure infections. J Antimicrob Chemother 2021; 76:1315���1322.
  34. Ramirez J, Deck DH, Eckburg PB, et al. Efficacy of omadacycline versus moxifloxacin in the treatment of community-acquired bacterial pneumonia by disease severity: results from the OPTIC Study. Open Forum Infect Dis 2021; 8:ofab135.
  35. Moran GJ, Chitra S, McGovern PC. Efficacy and safety of omadacycline versus linezolid in acute bacterial skin and skin structure infections in persons who inject drugs. Infect Dis Ther 2022; 11:517���531.
  36. Zurawski DV, Serio AW, Black C, et al. A review of omadacycline for potential utility in the military health system for the treatment of wound infections. Mil Med 2024; 189:e1353���e1361.
  37. O���Riordan W, Green S, Overcash JS, et al. Omadacycline for Acute Bacterial Skin and Skin-Structure Infections. N Engl J Med 2019; 380:528���538.
  38. Sakoulas G, Eckburg PB, Amodio-Groton M, et al. Clinical efficacy of patients with secondary bacteremia treated with omadacycline: results from Phase 3 acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia studies. Open Forum Infect Dis 2021; 8:ofab136.
  39. Van Anglen LJSC, Couch KA. Real-world use of omadacycline in Physician Office Infusion Centers (POICs). Open Forum Infect Dis 2022; 9: (Suppl 2): ofac492.857.
  40. Morrisette T, Alosaimy S, Lagnf AM, et al. Real-world, multicenter case series of patients treated with oral omadacycline for resistant Gram-negative pathogens. Infect Dis Ther 2022; 11:1715���1723.
  41. Ghali AEAS, Morrisette T, Molina KC, et al. A multi-center evaluation of omadacycline for multi-drug resistant infections. Open Forum Infect Dis 2022; 9: (Suppl 2): ofac492.1251.
  42. Wrotslavsky P. Empiric treatment approach for the management of postoperative incisional infections with omadacycline. Foot Ankle Surg 2023; 3:100263.

MeSH Term

Humans
Soft Tissue Infections
Tetracyclines
Anti-Bacterial Agents
Treatment Outcome
Skin Diseases, Bacterial
Skin Diseases, Infectious

Chemicals

Tetracyclines
omadacycline
Anti-Bacterial Agents
Journal Article Review
Article has an altmetric score of 2

Word Cloud

Created with Highcharts 10.0.0treatmentinfectionsSSTIscurrentevidenceomadacyclineskinsofttissueclinicalpotentialroleOmadacyclineparticularlybeyondPURPOSEOFREVIEW:evaluateuseRECENTFINDINGS:narrativereviewexaminesavailabledatapharmacologyefficacysafetyprofilecomparativeeffectivenesstreatingfocuseverydaypracticeSUMMARY:viableoptionoutpatienttherapyearlydischargepatientsfrailpopulationsundergoingchronicpolypharmacotherapyEmergingreal-worldhighlightsutilityapprovedindicationscausedmultidrug-resistantmicroorganismsoptionslimitedHoweverstudiesneededconfirmcontextsapprovals

Similar Articles

Cited By

No available data.